Novo Nordisk Juggles Buyback Power and Pill Rollout as Medicare Entry Ratchets Up the Stakes
Published on 06/25/2026 at 11:16 | Redaktion boerse-global.de
Novo Nordisk’s stock has clawed back above a critical technical threshold, yet the foundation of that rally is anything but solid. The Danish drugmaker has deployed a heavy?handed share?repurchase campaign alongside fresh clinical milestones to prop up investor confidence, even as the pricing outlook for its flagship obesity treatment turns increasingly hostile. The real test of whether this momentum can hold will come when Medicare opens its doors to GLP-1 drugs in July 2026 — a catalyst that could either turbocharge volumes or expose the limits of Novo’s pricing power.
Since February, the company has been ploughing 15 billion Danish kroner into a buyback scheme. In mid?June alone it scooped up more than one million of its own shares, bringing the total to nearly 21 million. That supply?side squeeze has helped push the share price to €42.08, reclaiming the 200?day moving average at €40.97. But the stock is still nursing a year?to?date loss of roughly six per cent, and the relative strength index now sits near 71 — a level that historically signals overbought conditions and raises the risk of profit?taking.
The immediate positive catalyst came from Britain’s approval of a once?daily Wegovy tablet, the first oral GLP?1 formulation to reach the market. Analysts view the pill as a game?changer in a field where injectable products are approaching saturation. In the United States the oral version has already racked up more than three million prescriptions in just five months — one of the fastest launch trajectories in recent pharma history. Crucially, over 80 per cent of those scripts went to patients new to GLP?1 therapy, implying the pill is expanding the addressable pool rather than cannibalising existing injectable sales.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
That expansion dovetails with the Medicare GLP?1 Bridge Program, which from 1 July 2026 will give up to 20 million US seniors access to weight?loss medicines including Wegovy. Patients will pay $50 a month, while manufacturers have agreed to a per?patient price ceiling of $245 per monthly supply. The volume opportunity is enormous, but the arithmetic is unforgiving: Novo Nordisk’s own guidance for full?year 2026 calls for a revenue decline of between five and 13 per cent, and adjusted US sales already dropped 11 per cent in the first quarter as net prices eroded.
Pipeline news offers a partial offset. At a June medical conference the company presented data on CagriSema, a combination therapy that delivered an average 23 per cent weight loss after 84 weeks. That lags behind Eli Lilly’s Zepbound, which achieved 25.5 per cent, and Lilly already commands 60 per cent of the US market versus Novo’s 39 per cent. A second experimental candidate, Zenagamtide, showed stronger relative results — nearly 15 per cent weight loss in phase 2 — and is expected to enter phase 3 in the second half of the year. Meanwhile, European regulators are reviewing the Wegovy pill for approval.
To help offset the pricing headwinds, the company is cutting 9,000 jobs under its new chief executive. The restructuring aims to save roughly eight billion Danish kroner by the end of 2026, though investors are watching whether the cuts will slow the research engine. Novo has also invested in its environmental credentials: a newly signed contract will reforest 500 hectares in the Brazilian Amazon over 20 years, generating an estimated 87,000 carbon credits as part of a net?zero target for 2045.
The next inflection point arrives on 5 August 2026, when second?quarter results are due. Market watchers will focus on two numbers: the realised net price per Wegovy unit in the US and the early prescription volumes flowing from the Medicare bridge programme. If those data disappoint, the recent share recovery — which has already lifted the stock 11 per cent in a single week — could prove short?lived. The support level at €40.97 will be the first line of defence; a clean break below it would signal that the long?term uptrend is no longer intact.
Ad
Novo Nordisk Stock: New Analysis - 25 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
